Experimental drug shows promise in slowing symptoms of Alzheimer's disease

An experimental drug is showing promise in slowing symptoms of Alzheimer’s disease. It’s called donanemab, and it’s a monoclonal antibody. “It gets in to the brain, in low doses, low concentrations. It binds to the plaque clumps in the brain and then it stimulates the immune system to break up the plaques which is then cleared through the blood system,” said Dr. Stephen Salloway, director of the Memory and Aging Program at Butler Hospital. He said the pandemic did not impact research.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Copy link
Powered by Social Snap